Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.709
https://www.valueinhealthjournal.com/article/S1098-3015(14)02639-4/fulltext
Title :
Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02639-4&doi=10.1016/j.jval.2014.08.709
First page :
A347
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
133